LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: Treatment outcome and risk factor analysis from a single centre

Hematological Oncology

Volumn 29, Issue 2, 2011, Pages 75-80

  Pavlů, Jiří ^a   Auner, Holger W ^a   Ellis, Sarah ^a   Szydlo, Richard M ^a   Giles, Chrissy ^a   Contento, Alejandro ^b   Rahemtulla, Amin ^a   Apperley, Jane F ^a   Naresh, Kikkeri ^c   Macdonald, Donald H ^a   Kanfer, Edward J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Autologous stem cell transplantation; C reactive protein (CRP); Diffuse large B cell lymphoma; High dose chemotherapy

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; LOMUSTINE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CANCER RELAPSE; CHEMOSENSITIVITY; CONTROLLED STUDY; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RISK ASSESSMENT; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DIARRHEA; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LOMUSTINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; STOMATITIS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 79959213938     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.956     Document Type: Article

References (28)

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717-720.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
4. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
5. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399-2404.
6. Vose JM, Zhang M-J, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry (ABMTR). J Clin Oncol 2001; 19: 406-413.
7. Philip T, Armitage JO, Spitzer O, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1498.
8. Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007; 39: 41-47.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1257.
10. Shank B. Total body irradiation for marrow or stem-cell transplantation. Cancer Invest 1998; 16: 397-404.
11. Aristei C, Tabilio A. Total-body irradiation in the conditioning regimens for autologous stem cell transplantation in lymphoproliferative diseases. Oncologist 1999; 4: 386-397.
12. Gutierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 2001; 28: 455-461.
13. Salar A, Sierra J, Gandarillas M, et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27: 405-412.
14. Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
15. Caballero MD, Perez-Simon JA, Iriondo A, et al. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140-151.
16. Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (>60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation Registry. Haematologica 2008; 93: 1837-1842.
17. Kumar N, Joshi A, Shah M, et al. Comparison of toxicity of BEAM versus LACE regimen in patients with lymphoma. Bone Marrow Transplant 2009; 43 (Suppl 1): S209 (abstract P755).
18. Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593-599.
19. Jantunen E, Itälä M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006; 37: 367-372.
20. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens-a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48-55.
21. Wheeler C, Strawderman M, Ayash L, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 19: 1085-1091.
22. van Besien K, Tabocoff J, Rodriquez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549-555.
23. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56: 5499-5505.
24. Pavlidis AN, Kalef-Ezra J, Bourantas LC, Lambrou A, Mavridis A. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Int J Biol Markers 1993; 8: 14-20.
25. Legouffe E, Rodriguez C, Picot MC, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998; 31: 351-357.
26. Herishanu Y, Perry C, Braunstein R, et al. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Eur J Hematol 2007; 79: 150-154.
27. Artz AS, Wickrema A, Dinner S, et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 1209-1216.
28. Pavlu J, Kew A, Taylor-Roberts B, et al. Optimizing patient selection for allogeneic hematopoietic cell transplantation in chronic myeloid leukaemia in chronic phase. Blood 2010; 115: 4018-4020.